Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial
Open Access
- 12 November 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 16 (11), e1002960
- https://doi.org/10.1371/journal.pmed.1002960
Abstract
Young male cancer survivors have lower testosterone levels, higher fat mass, and worse quality of life (QoL) than age-matched healthy controls. Low testosterone in cancer survivors can be due to orchidectomy or effects of chemotherapy and radiotherapy. We have undertaken a double-blind, placebo-controlled, 6-month trial of testosterone replacement in young male cancer survivors with borderline low testosterone (7–12 nmol/l). This was a multicentre United Kingdom study conducted in secondary care hospital outpatients. Male survivors of testicular cancer, lymphoma, and leukaemia aged 25–50 years with morning total serum testosterone 7–12 nmol/l were recruited. A total of 136 men were randomised between July 2012 and February 2015 (42.6% aged 25–37 years, 57.4% 38–50 years, 88% testicular cancer, 10% lymphoma, matched for body mass index [BMI]). Participants were randomised 1:1 to receive testosterone (Tostran 2% gel) or placebo for 26 weeks. A dose titration was performed after 2 weeks. The coprimary end points were trunk fat mass and SF36 Physical Functioning score (SF36-PF) at 26 weeks by intention to treat. At 26 weeks, testosterone treatment compared with placebo was associated with decreased trunk fat mass (−0.9 kg, 95% CI −1.6 to −0.3, p = 0.0073), decreased whole-body fat mass (−1.8 kg, 95% CI −2.9 to −0.7, p = 0.0016), and increased lean body mass (1.5 kg, 95% CI 0.9–2.1, p < 0.001). Decrease in fat mass was greatest in those with a high truncal fat mass at baseline. There was no treatment effect on SF36-PF or any other QoL scores. Testosterone treatment was well tolerated. The limitations of our study were as follows: a relatively short duration of treatment, only three cancer groups included, and no hard end point data such as cardiovascular events. In young male cancer survivors with low-normal morning total serum testosterone, replacement with testosterone is associated with an improvement in body composition. ISRCTN: 70274195, EudraCT: 2011-000677-31.Funding Information
- Cancer Research UK (R/126349)
This publication has 32 references indexed in Scilit:
- Hypothalamic–Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society* Clinical Practice GuidelineJournal of Clinical Endocrinology & Metabolism, 2018
- Testosterone deficiency in testicular cancer survivors – a systematic review and meta‐analysisAndrology, 2016
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in AdultsJournal of the American College of Cardiology, 2014
- Medication Adherence and Treatment Patterns for Hypogonadal Patients Treated with Topical Testosterone Therapy: A Retrospective Medical Claims AnalysisThe Journal of Sexual Medicine, 2013
- Increased frequency of anxiety, depression, quality of life and sexual life in young hypogonadotropic hypogonadal males and impacts of testosterone replacement therapy on these conditionsEndocrine Journal, 2012
- Onset of effects of testosterone treatment and time span until maximum effects are achievedActa Endocrinologica, 2011
- Chronic Health Conditions in Adult Survivors of Childhood CancerThe New England Journal of Medicine, 2006
- Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men1Journal of Clinical Endocrinology & Metabolism, 2000
- Testosterone Replacement Increases Fat-Free Mass and Muscle Size in Hypogonadal Men1Journal of Clinical Endocrinology & Metabolism, 1997
- Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men--a clinical research center study.Journal of Clinical Endocrinology & Metabolism, 1996